Flexion Therapeutics Inc (FLXN): Neil Bodick , Chief Medical Officer of Flexion Therapeutics Inc purchased 2,100 shares on May 18, 2016. The Insider buying transaction was reported by the company on May 19, 2016 to the Securities and Exchange Commission. The shares were purchased at $10.20 per share for a total value of $21,420.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Frederick W Driscoll (CFO) purchased 2,500 shares at $9.87 per share price.On May 18, 2016, Neil Bodick (Chief Medical Officer) purchased 800 shares at $9.60 per share price.Also, On May 18, 2016, Michael D. Clayman (CEO) purchased 2,000 shares at $9.73 per share price.On Sep 14, 2015, C Ann Merrifield (director) purchased 1,000 shares at $23.00 per share price.
Shares of Flexion Therapeutics Inc (FLXN) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.56 points or -5.47% at $9.68 with 1,47,298 shares getting traded. Post opening the session at $10.23, the shares hit an intraday low of $9.45 and an intraday high of $10.64 and the price vacillated in this range throughout the day. The company has a market cap of $208,798 M and the number of outstanding shares has been calculated to be 21,57,00,00,000 shares. The 52-week high of Flexion Therapeutics Inc is $29.09 and the 52-week low is $7.56.
Company has been under the radar of several Street Analysts.Flexion Therapeutics Inc is Resumed by Wells Fargo to Outperform. The Rating was issued on May 3, 2016.
Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.